Autor:	M B, Agarwal
Rok vydání:	2006
Předmět:	Models Structural Deferasirox beta-Thalassemia Administration Oral Humans Triazoles Iron Chelating Agents Benzoates Randomized Controlled Trials as Topic
Zdroj:	The Journal of the Association of Physicians of India. 54
ISSN:	0004-5772
Popis:	ICL670(deferasirox) is a tridentate oral iron chelator that has shown high efficacy and theraputic safety in preclinical and currently ongoing phase III clinical evaluation. The drug has been just approved by US FDA for use in iron-loading anaemias. It is an ideal once-daily oral chelator, the effective dose of which is between 20 and 40 mg/kg. Iron is chelatedexcreted almost exclusively via the feces. This is a major advance in the field of iron chelation.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::b9ce7e5baaab03fb847ae143ea69fbb0 https://pubmed.ncbi.nlm.nih.gov/16800349 Zobrazit plný text záznamu